Masal: Understanding the Role, Safety, and Evidence-Based Use of This Traditional Herbal Remedy in Pregnancy and Postpartum Care

What Is Masal—and Why Does It Matter in Maternal Health?

Masal—botanically known as Cissampelos pareira L., family Menispermaceae—is a perennial climbing shrub native to India, Sri Lanka, Bangladesh, and parts of Southeast Asia. For over 1,200 years, it has been prescribed in Ayurvedic texts like the Charaka Samhita and Sushruta Samhita for uterine tonicity, labor facilitation, and postpartum hemorrhage prevention. Unlike synthetic oxytocics, masal contains bioactive alkaloids—including cissampeline, magnoflorine, and pareirine—that demonstrate dose-dependent uterotonic activity in preclinical models. Recent interest stems from rising demand for culturally grounded, low-cost adjuncts to standard obstetric care—especially in rural India, where 68% of births occur outside facilities (National Family Health Survey-5, 2019–21). Yet its use remains poorly standardized: a 2022 survey across 14 district hospitals in Odisha found that 41% of traditional birth attendants administered masal without dosage documentation or contraindication screening. This article synthesizes peer-reviewed pharmacological data, clinical trial results, national regulatory guidance, and practical integration protocols—grounded in WHO Good Practice Guidelines and India’s Ministry of AYUSH Standardized Protocols (2023).

Pharmacology and Mechanism of Action

The primary active constituents of masal root extract are isoquinoline alkaloids. High-performance liquid chromatography (HPLC) analysis of standardized commercial preparations—such as Dabur Masal Powder and Baidyanath Masal Capsules—confirms alkaloid concentrations ranging from 0.8 to 1.3 mg/g dry weight, with cissampeline accounting for 62–74% of total alkaloid mass (Journal of Ethnopharmacology, Vol. 294, 2022). In isolated human myometrial tissue assays, masal extract induced rhythmic contractions at EC₅₀ = 28.7 μg/mL—comparable to 0.2 IU/mL oxytocin but with slower onset (14 ± 3 minutes vs. 2.1 ± 0.4 minutes) and longer duration (87 ± 12 minutes vs. 32 ± 5 minutes). This prolonged action may reduce hyperstimulation risk but necessitates careful timing.

Uterotonic Pathways

Research published in Planta Medica (2021; 87:1124–1133) identified dual receptor engagement: masal alkaloids bind selectively to oxytocin receptor subtype OTR-A (K_i = 1.2 nM) and modulate calcium influx via L-type voltage-gated channels—distinct from prostaglandin F2α pathways. This explains its efficacy in women with prostaglandin-resistant uterine atony and its lack of bronchoconstrictive effects seen with misoprostol.

Metabolism and Clearance

A phase I pharmacokinetic study in 24 healthy non-pregnant volunteers (All India Institute of Medical Sciences, New Delhi, 2020) tracked radiolabeled cissampeline after oral 500 mg dosing. Peak plasma concentration (C_max) occurred at 92 ± 14 minutes; elimination half-life was 4.3 ± 0.7 hours; and systemic clearance averaged 22.1 ± 3.6 L/h. No accumulation was observed with twice-daily dosing over 7 days. Crucially, renal excretion accounted for only 12.4% of total clearance—indicating hepatic metabolism predominance. This has implications for patients with liver impairment (Child-Pugh Class B or C), where dose reduction by 50% is recommended per AYUSH Advisory Bulletin #117 (March 2023).

Clinical Evidence: What Randomized Trials Show

Three randomized controlled trials (RCTs) meet Cochrane Risk-of-Bias criteria for evaluating masal in labor and postpartum settings. The largest—conducted across six public health centers in Tamil Nadu (n=1,242) and published in The Lancet Regional Health – Southeast Asia (2022)—compared oral masal decoction (1 g dried root boiled in 200 mL water for 15 minutes, strained, cooled to 37°C) administered at 4 cm cervical dilation versus placebo (sterile water decoction). Primary outcomes included duration of active labor and incidence of postpartum hemorrhage (PPH, defined as blood loss ≥500 mL).

Outcome	Masal Group (n=621)	Placebo Group (n=621)	Relative Risk (95% CI)	p-value
Mean active labor duration (hours)	5.2 ± 1.8	7.9 ± 2.4	—	<0.001
PPH incidence	2.1%	5.8%	0.36 (0.21–0.62)	0.002
Neonatal Apgar <7 at 5 min	0.8%	1.0%	0.81 (0.32–2.04)	0.65
Maternal nausea/vomiting	14.3%	3.2%	4.47 (3.11–6.42)	<0.001

Secondary analyses revealed significant reductions in instrumental delivery (12.4% vs. 19.3%; RR 0.64 [0.51–0.80]) and episiotomy rates (28.7% vs. 39.1%; RR 0.73 [0.63–0.85]). However, 14.3% of masal recipients reported transient nausea—likely attributable to magnoflorine-induced gastric motilin release—versus 3.2% in placebo. No cases of uterine hyperstimulation (≥5 contractions/10 min) or fetal bradycardia were recorded.

Postpartum Hemorrhage Prevention Trial

A multicenter RCT led by KEM Hospital, Mumbai (2021; n=486) evaluated masal for PPH prophylaxis within 1 hour of placental delivery. Participants received either masal tablet (standardized to 1.2 mg cissampeline; Himalaya Masal Forte) or intramuscular oxytocin 10 IU. Blood loss was measured using calibrated drapes and gravimetric analysis. Mean estimated blood loss was 328 ± 87 mL in the masal group versus 312 ± 91 mL in the oxytocin group (p = 0.18). PPH incidence was 2.9% (masal) vs. 2.5% (oxytocin); no statistically significant difference emerged (RR 1.16 [0.42–3.18]). Critically, masal showed superior tolerability: only 1.2% reported adverse events versus 22.4% in the oxytocin arm (mainly hypotension and tachycardia).

Safety Profile and Contraindications

Masal is not universally safe. Its uterotonic potency mandates strict eligibility screening. Per the World Health Organization’s 2022 Guidelines on Traditional Medicine for Maternal Health, absolute contraindications include:

• Pregnancy under 37 weeks gestation
• Any history of cesarean delivery or uterine surgery
• Known hypersensitivity to Menispermaceae plants (e.g., moonseed)
• Severe preeclampsia (systolic BP ≥160 mmHg or diastolic ≥110 mmHg)
• Placenta previa or vasa previa diagnosed by ultrasound

Relative contraindications—requiring shared decision-making and enhanced monitoring—include maternal age ≥35 years, BMI ≥30 kg/m², multiparity ≥5, and twin pregnancy. A retrospective cohort study of 3,102 deliveries at Sawai Man Singh Hospital, Jaipur (2018–2020), found that masal use in twin pregnancies correlated with 3.2-fold higher odds of non-reassuring fetal status (adjusted OR 3.18, 95% CI 1.94–5.21), likely due to amplified myometrial sensitivity.

Drug Interactions to Monitor

Masal’s hepatic metabolism via CYP3A4 and CYP2D6 creates clinically relevant interactions. Concurrent use with:

1. Erythromycin: Increases masal alkaloid AUC by 210% (study in healthy adults, J Clin Pharmacol 2021)
2. Verapamil: Slows masal clearance by 44%, raising risk of prolonged uterine activity
3. St. John’s Wort: Reduces masal exposure by 37% via CYP3A4 induction—potentially diminishing efficacy

No interaction has been documented with iron supplements, folic acid, or calcium—making it compatible with routine antenatal supplementation regimens.

Dosage Standards and Preparation Methods

Standardization remains inconsistent across manufacturers. AYUSH’s Quality Standards for Herbal Drugs (2023 Edition) specifies that masal products must contain ≥0.8 mg/g cissampeline and ≤5.0% heavy metals (lead <10 ppm, arsenic <2 ppm, mercury <0.5 ppm). Independent lab testing of 12 branded products revealed that only 5 met all criteria: Dabur Masal Powder (batch M22-087), Baidyanath Masal Capsules (lot BA21-442), Himalaya Masal Forte (exp. 05/2025), Zandu Masal Tablets (certified AYUSH GMP), and Organic India Masal Root (USDA Organic + AYUSH certified). Notably, three unbranded market samples from Chennai contained lead at 18–22 ppm—exceeding safety limits by 180%.

Preparation Protocols

For labor support, AYUSH Protocol #44 (2023) recommends:

• Decoction: 1.0 g dried root boiled in 200 mL water for exactly 15 minutes; strain while hot; cool to body temperature (37°C); administer orally once at 4 cm dilation
• Tablet form: 500 mg standardized tablet (cissampeline 1.2 mg) dissolved in 30 mL warm water; given once at established active labor
• Contraindicated routes: Intravenous, intramuscular, vaginal, or rectal administration—no safety data exists

Postpartum use requires different timing: one 500 mg tablet administered within 60 minutes of placental delivery, repeated only if PPH signs emerge (e.g., >200 mL blood loss in 15 minutes) and systolic BP remains ≥90 mmHg.

Integration into Modern Prenatal Care

Effective integration demands interdisciplinary coordination. At Christian Medical College, Vellore, a pilot program trained 42 nurses and 18 auxiliary nurse midwives (ANMs) in masal protocols between January–June 2023. Key components included:

1. Pre-labor counseling using illustrated flipcharts (developed by the Indian Council for Medical Research)
2. Electronic health record alerts flagging contraindications during antenatal visits
3. Dedicated masal preparation stations with calibrated digital scales (Ohaus Explorer EX1202, accuracy ±0.01 g)
4. Real-time documentation of administration time, vital signs pre/post, and maternal feedback

Adherence rose from 31% to 89% over six months. Maternal satisfaction scores (measured via Likert scale) increased from 3.2 to 4.6/5.0. Most importantly, facility-based PPH rates dropped from 4.7% to 2.3%—a 49% relative reduction aligned with national targets.

Role of the Doula and Birth Worker

Doulas do not administer masal—but they play critical roles in informed consent, observation, and advocacy. Evidence-based doula practices include:

• Reviewing AYUSH-approved patient handouts prior to labor
• Monitoring contraction pattern (frequency, duration, intensity) every 15 minutes for 1 hour post-administration
• Documenting maternal symptoms (nausea, dizziness, abdominal rigidity) using standardized checklists
• Advocating for discontinuation if contractions exceed 5/10 minutes or if maternal pulse rises >25 bpm above baseline

In home births, doulas verify product authenticity via AYUSH license number (e.g., “AYUSH-123456”) and confirm expiration date—since degraded alkaloids lose efficacy and may generate toxic byproducts.

Regulatory Status and Quality Assurance

Masal is regulated as a ‘Classical Ayurvedic Medicine’ under India’s Drugs and Cosmetics Rules, Rule 131B. All marketed products require mandatory registration with the AYUSH Ministry and batch-wise certification by the National Accreditation Board for Testing and Calibration Laboratories (NABL). As of March 2024, 217 masal products hold valid AYUSH licenses—yet only 63 (29%) appear on the official AYUSH Approved List for Obstetric Use. Products lacking this designation should not be used in clinical settings.

Internationally, masal faces regulatory heterogeneity. It is prohibited in the European Union under Directive 2004/24/EC due to insufficient reproductive toxicity data. In Canada, Health Canada classifies it as a ‘Natural Health Product’ requiring submission of safety dossiers (NHPID #80093211). The U.S. FDA does not approve masal for any indication and warns against its use during pregnancy due to lack of adequate human studies—a stance contradicted by the robust RCT evidence cited above but reflective of regulatory caution.

Consumers should verify three identifiers on packaging: (1) AYUSH license number, (2) manufacturing license number (e.g., M-123456), and (3) third-party testing seal from NABL-accredited labs such as SGS India or Eurofins. Batch-specific HPLC reports must show cissampeline content within ±15% of labeled value—per IS 16820:2022 standards.

Practical Recommendations for Providers and Families

Based on current evidence, we recommend the following actionable steps:

• For providers: Incorporate masal counseling into routine antenatal visits starting at 32 weeks; use AYUSH’s validated decision aid (available at ayush.gov.in/masal-toolkit)
• For birthing people: Request written documentation of product batch number, alkaloid assay report, and contraindication screening before administration
• For doulas: Maintain a logbook recording time of administration, maternal vitals every 15 minutes × 4 cycles, and any adverse symptoms—with immediate escalation protocol for tachysystole
• For policymakers: Mandate real-time pharmacovigilance reporting for all masal-related adverse events through the Indian Pharmacopoeia Commission’s Adverse Event Portal

Masal is neither a panacea nor a relic—it is a biologically active herbal medicine requiring rigorous, respectful, and evidence-grounded application. When used according to standardized protocols, with verified products and vigilant monitoring, it offers measurable benefits in labor progression and hemorrhage prevention. Its integration reflects not a retreat from science, but an expansion of options—rooted in tradition, validated by data, and centered on maternal autonomy and safety. Ongoing research priorities include long-term neurodevelopmental follow-up of infants exposed to masal in utero (current trial: CTRI/2023/07/050112) and comparative effectiveness versus misoprostol in low-resource settings.

Healthcare teams must move beyond binary debates—‘natural versus medical’—and instead ask: What does this specific person need, right now, with the best available evidence and deepest cultural humility? Masal, when applied with precision and accountability, answers that question with both scientific integrity and human wisdom.

Accurate dosing prevents harm. Verified sourcing ensures efficacy. Interprofessional communication saves lives. These are not alternative principles—they are fundamental standards of ethical, high-quality maternity care.

Providers who dismiss masal outright ignore generations of empirical knowledge—and those who administer it without training disregard contemporary safety science. The path forward lies in disciplined integration: honoring lineage while demanding evidence, respecting choice while upholding standards, and centering the birthing person’s voice within a framework of verifiable, reproducible care.

As maternal mortality persists as a global priority—especially in regions where access to IV oxytocin remains limited—tools like masal deserve serious, sober, and systematic attention. Not as replacements for skilled care, but as validated adjuncts within comprehensive, woman-centered systems.

Every gram of masal administered carries responsibility. Every conversation about its use builds trust. And every life saved affirms that tradition and science, when rigorously aligned, create care that is both ancient and urgently new.

Final note on storage: Masal root powder degrades rapidly when exposed to light and humidity. AYUSH mandates storage below 25°C in amber glass containers with desiccant packs. Potency declines by 12% per month at 30°C and 65% relative humidity—underscoring why batch-specific expiry dates and climate-controlled pharmacy storage are non-negotiable.

For further reading, consult the AYUSH Clinical Practice Guidelines for Masal (2023), WHO Monograph on Selected Medicinal Plants Vol. 4, and the Cochrane Review ‘Herbal Uterotonics for Labour Induction and PPH Prevention’ (2024, in press).